Department of Pathology, Inha University Hospital, Inha University School of Medicine, Incheon, Korea
© 2014 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PubReader
ePub Link
Cite this Article
| Target | Source | Dilution |
|---|---|---|
| Cytokeratin 19 | Dako | 1:200 |
| Galectin-3 | Novocastra | 1:500 |
| Thyroid transcription factor-1 | NeoMarkers | 1:1,500 |
| Thyroglobulin | NeoMarkers | 1:1,500 |
| Parathyroid hormone | NeoMarkers | 1:400 |
| CD56 | Novocastra | 1:400 |
| HBME1 | Cell Marque | 1:400 |
| D2-40 | Dako | 1:300 |
| Wilms’ tumor-1 | Cell Marque | 1:500 |
| Calretinin | Chemicon | 1:1,800 |
| Leukocyte common antigen (CD45) | Dako | 1:2,000 |
| CD20 | Pharmingen | 1:100 |
| CD3 | Dako | 1:100 |
| Terminal deoxynucleotidyl transferase | Cell Marque | 1:400 |
| PAX5 | Cell Marque | 1:400 |
| Samples | Site | Diagnosis of smears | Supportive immunocytochemistry of cell block* | Diagnosis based on ICC |
|---|---|---|---|---|
| LBC_FNAs (SurePath) | Thyroid | Papillary carcinoma (n=8) | TG+, TTF1+, CK19+, galectin 3+, CD56–, HBME1+, PTH– | Papillary thyroid carcinoma |
| Suspicious for papillary carcinoma (n=2) | TG+, TTF1+, CK19+, galectin 3+, CD56–, HBME1+, PTH– | Papillary thyroid carcinoma | ||
| Nodular hyperplasia (n=12) | TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– | Nodular hyperplasia | ||
| Atypia (n=4) | TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– | Nodular hyperplasia | ||
| Atypia (n=1) | TG–, TTF1–, CK19+, galectin 3–, CD56–, HBME1–, PTH+ | Parathyroid lesion | ||
| Benign Hurthle cell proliferation (n=2) | TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– | Benign Hurthle cell lesion | ||
| Chronic lymphocytic thyroiditis (n=2) | N/A due to scanty cellularity | N/A | ||
| Lymph node | Lymphoid malignancy (n=2) | CD45–, CD20–, CD3–, TdT+, PAX5+, CD56– | B-lymphoblastic lymphoma | |
| CD45+, CD20+, CD3–, TdT–, PAX5+, CD56– | Large B-cell lymphoma | |||
| LBC_serous effusions (SurePath) | Ascitic fluid | Lymphoid malignancy (n=1) | CD45+, CD20–, CD3–, TdT+, PAX5+, CD56– | B-lymphoblastic lymphoma |
| Adenocarcinoma (n=1) | CK7+, CK19+, calretinin–, D2-40, WT1+, CD56–, TTF1– | Ovarian serous carcinoma | ||
| Pleural effusion | Adenocarcinoma (n=1) | CK7+, CK19+, calretinin–, D2-40–, HBME1–, WT1–, TTF1+ | Adenocarcinoma of lung primary | |
| Favor malignant mesothelioma (n=1) | CK7+, CK19+, calretinin+, D2-40+, HBME1+, WT1+, TTF1– | Malignant mesothelioma | ||
| Negative for malignancy (n=1) | N/A | N/A |
ICC, immunocytochemistry; LBC, liquid-based cytology; FNA, fine needle aspiration; cytokeratin; TG, thyroglobulin; TTF1, thyroid transcription factor-1; CK, cytokeratin; PTH, parathyroid hormone; N/A, not applicable; TdT, terminal deoxynucleotidyl transferase; WT1, Wilms’ tumor-1.